Memorial Hospital Research Laboratories

The Elli Papaemmanuil Lab

Share
Print
Back to Top

Research

Eli Papemmanuil
Elli Papaemmanuil, PhD

Our lab is a collective of clinical, computational, molecular and mathematic research investigators with an interest in studying the role of acquired mutations in cancer development, and how these determine clinical phenotype and response to therapy. Our mission is to execute research that informs and moves clinical practices in oncology forward. We have strong expertise in genome profiling analysis, a proven track record on the development of high-throughput laboratory and analytical pipelines (bioinformatics and statistical), and integrating large and complex genomic datasets. We have formed a strong network of research and clinical collaborations to pursue innovative studies in cancer research.

We like to perform ambitious research, but operate in a fun, collaborative, and team-oriented environment, and we are strongly committed to mentoring young scientists through internal and international internship schemes.

View Lab Overview

Research Projects

The Elli Papaemmanuil Lab

Featured News

In the Clinic
Molecular geneticist Elli Papaemmanuil
New Research Shows AML Is Not One Disease, But 11 or More

MSK molecular geneticist Elli Papaemmanuil.
Large International Study Pinpoints Impact of TP53 Gene Mutations on Blood Cancer Severity

Finding
Researchers Ahmet Zehir and Elli Papaemmanuil talk while looking at a computer.
Why Do Certain Chemotherapies Increase the Likelihood of Blood Cancer?

Publications

Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, Titley I, Stebbings L, Leroy C, Menzies A, Gamble J, Robinson B, Mudie L, Raine K, O’Meara S, Teague JW, Butler AP, Cazzaniga G, Biondi A, Zuna J, Kempski H, Muschen M, Ford AM, Stratton MR, Greaves M, Campbell PJ. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014 Feb;46(2):116-25. doi: 10.1038/ng.2874. Epub 2014 Jan 12. PubMed Central PMCID: PMC3960636. PubMed

Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901. PubMed Central PMCID: PMC4338540. PubMed

Gerstung M, Papaemmanuil E, Campbell PJ. Subclonal variant calling with multiple samples and prior knowledge. Bioinformatics. 2014 May 1;30(9):1198-204. doi: 10.1093/bioinformatics/btt750. Epub 2014 Jan 16. PubMed Central PMCID: PMC3998123. PubMed

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O’Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12. PubMed Central PMCID: PMC3837510. PubMed

Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Tomlinson IP, Taylor M, Greaves M, Houlston RS. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009 Sep;41(9):1006-10. doi: 10.1038/ng.430. Epub 2009 Aug 16. PubMed

View All Publications

People

Eli Papemmanuil

Elli Papaemmanuil, PhD

  • Molecular geneticist Elli Papaemmanuil performs systematic interrogations of well-annotated clinical trial cohorts in leukemia and cancer to explore how the compound genetic and clonal architecture in patients' leukemias and tumors dictate clinical phenotype, disease progression, and clinical outcomes.
  • PhD – University of London, London, England, UK
[email protected]
Email Address
646-608-7645
Office Phone

Members

Juan E. Arango-Ossa

Bioinformatics Engineer III

Georgios Asimomitis, Computational Biologist II
Georgios Asimomitis

Computational Biologist II

Elsa Bernard, PhD
Elsa Bernard

Research fellow

Dylan Domenico
Dylan Domenico

Bioinformatics Engineer I

Gunes Gundem, Senior Research Scientist
Gunes Gundem

Senior Research Scientist

Jesus, Gutierrez-Abril, Research Fellow
Jesus Gutierrez-Abril

Research Fellow

Max Levine
Max Levine

Senior Computational Biologist I

Joseph G. McCarter
Joseph G. McCarter

Computational Biologist, Sr I

Noushin Rahnamay Farnoud
Noushin Rahnamay Farnoud

Computational Biologist, Sr II

Kayleigh Rutherford, Computational Biologist II
Kayleigh Rutherford

Computational Biologist II

Jake Sauter

WCM Graduate Student

Sarun Sereewattanawoot
Sarun Sereewattanawoot

Research Fellow

Maria Sirenko, Graduate Student
Maria Sirenko

GSK Graduate Student

Yanis Tazi, Graduate Student, Tri-I Institutional PhD Program
Yanis Tazi

Graduate Student, Tri-I Institutional PhD Program

Lab Alumni
Seon Ball

Administrative Assistant II

Antonin Berthon

Graduate Research Assistant

Maheetha Bharadwaj, Computational Biologist I
Maheetha Bharadwaj

Computational Biologist I

Kelly Bolton
Kelly Bolton

Instructor

Matthieu Cornet

Graduate Research Assistant

Robert de Massy
Marc Robert de Massy

Visiting scientists

Andre Deslauriers, Graduate Research Asst
Andre Deslauriers

Graduate Research Assistant

Teng Gao
Teng Gao

Computational Biologist II

Dominik Glodzik
Dominik Glodzik

Associate Manger, Computational Biologist

Pierre F. Guilmin

Graduate Research Assistant

Juan Medina
Juan Medina

Bioinformatics Engineer II, Leukemia Genomics

Matahi Moarii, Postdoctoral Fellow
Matahi Moarii

Research Fellow

Yoann Pradat, Graduate Research Asst
Yoann Pradat

Graduate Research Asst

Komal Rathi
Komal Rathi

Bioinformatics Engineer II, Leukemia Genomics

Yellapantula Venkata, Bioinformatics Engineer II
Yellapantula Venkata

Bioinformatics Engineer II

Elliot Youth
Elliot Youth

Intern

Yangyu Zhou, Bioinformatics Engineer I
Yangyu Zhou

Bioinformatics Engineer II

Lab Affiliations

Achievements

Open Positions

Bioinformatics Data Scientist

Apply now

Careers

Apply now

Molecular genomics, Research Assistant / Senior Research Technician

Apply now

View All Open Positions

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Elli Papaemmanuil discloses the following relationships and financial interests:

  • Isabl Technologies
    Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures